European Long-acting Antipsychotics in Schizofrenia Trial EULAST - EULAST

niversity Medical Center Utrecht0 个研究点目标入组 600 人开始时间: 2014年10月15日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•1.Diagnosis of schizophrenia as defined by DSM-IV-R as determined by the M.I.N.I.plus
•2.Age 18 or older.
•3.The first psychosis occurred at least one year and no more than 7 years ago.
•4.If patients are using an antipsychotic drug, a medication switch is currently under consideration.
•5.Capable of providing written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 600
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Intolerance / hypersensitivity to one of the drugs (including active substances, metabolites and excipients) in this study including oral risperidone, paliperidone and aripiprazole.
•2.Pregnancy or lactation.
•3. Patients who are currently using clozapine.
•4.Patients who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate.
•5.Patients with a documented history of non-response and/or intolerance to any of the study medications.
•6.Forensic patients.
•7.Patients who have been treated with an investigational drug within 30 days prior to screening.

发起方